![Roman Urfer](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Roman Urfer
Algemeen Directeur bij Selonterra, Inc.
Profiel
Roman Urfer is the founder and Chief Executive Officer of Selonterra, Inc. which is founded in 2015.
He is currently the Chief Development Officer at NeuroAssets Sàrl.
Dr. Urfer has previously worked as the Director & Chief Scientific Officer at M's Science Corp., Senior Vice President-Drug Discovery & Development at AGY Therapeutics, Inc., and as a Principal at Novartis Pharma AG.
He holds a doctorate from the University of Basel and an undergraduate degree from the Swiss Federal Institute of Technology.
Actieve functies van Roman Urfer
Bedrijven | Functie | Begin |
---|---|---|
NeuroAssets Sàrl | Corporate Officer/Principal | - |
Selonterra, Inc.
![]() Selonterra, Inc. BiotechnologyHealth Technology The American company focuses on developing therapies for neurodegenerative disorders such as Parkinson's and Alzheimer's disease. The company uses human genetics, molecular pathway analysis, and gene regulatory networks to identify disease-causing mechanisms and molecular targets to discover effective therapeutics. Selonterra's founders and advisors are experienced scientists and executives in the biotech and pharma industries, and they collaborate with other companies in their network. The company was founded by Anne Urfer-Buchwalder and Roman Urfer, with Roman Urfer serving as CEO since incorporation. | Algemeen Directeur | 01-12-2015 |
Eerdere bekende functies van Roman Urfer
Bedrijven | Functie | Einde |
---|---|---|
Novartis Pharma AG
![]() Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | - |
AGY Therapeutics, Inc.
![]() AGY Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AGY Therapeutics, Inc. develops new therapies for diseases and disorders. It develops central nervous system therapeutics for the treatments of neurodegenerative diseases, CNS injuries, stroke, and schizophrenia. The company was founded by Robert Swanson and Karoly Nikolich in 1998 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
M's Science Corp.
![]() M's Science Corp. Miscellaneous Commercial ServicesCommercial Services M's Science Corp. engages in the research and development of drugs for the treatment of central nervous system (CNS) disorders and ocular diseases. It develops Cutamesine, an orally active compound that enhances neuroregeneration and facilitates the recovery of damaged CNS tissues from stress or ischemia-induced insults. The firm also develops therapeutic drugs for oncology. The company was founded by Shiro Mita in November 2000 and is headquartered in Kobe, Japan. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Roman Urfer
University of Basel | Doctorate Degree |
Swiss Federal Institute of Technology | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 5 |
---|---|
AGY Therapeutics, Inc.
![]() AGY Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AGY Therapeutics, Inc. develops new therapies for diseases and disorders. It develops central nervous system therapeutics for the treatments of neurodegenerative diseases, CNS injuries, stroke, and schizophrenia. The company was founded by Robert Swanson and Karoly Nikolich in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Novartis Pharma AG
![]() Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
M's Science Corp.
![]() M's Science Corp. Miscellaneous Commercial ServicesCommercial Services M's Science Corp. engages in the research and development of drugs for the treatment of central nervous system (CNS) disorders and ocular diseases. It develops Cutamesine, an orally active compound that enhances neuroregeneration and facilitates the recovery of damaged CNS tissues from stress or ischemia-induced insults. The firm also develops therapeutic drugs for oncology. The company was founded by Shiro Mita in November 2000 and is headquartered in Kobe, Japan. | Commercial Services |
NeuroAssets Sàrl | |
Selonterra, Inc.
![]() Selonterra, Inc. BiotechnologyHealth Technology The American company focuses on developing therapies for neurodegenerative disorders such as Parkinson's and Alzheimer's disease. The company uses human genetics, molecular pathway analysis, and gene regulatory networks to identify disease-causing mechanisms and molecular targets to discover effective therapeutics. Selonterra's founders and advisors are experienced scientists and executives in the biotech and pharma industries, and they collaborate with other companies in their network. The company was founded by Anne Urfer-Buchwalder and Roman Urfer, with Roman Urfer serving as CEO since incorporation. | Health Technology |